戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 nerally consistent with the known profile of lisdexamfetamine.
2                                              Lisdexamfetamine administration.
3 ng relapse criteria were 3.7% (5 of 136) for lisdexamfetamine and 32.1% (42 of 131) for placebo.
4 inge eating and related psychopathology, and lisdexamfetamine and topiramate reduced weight in adults
5 amphetamine-based medication (dexamfetamine, lisdexamfetamine), and 24 controls (8 males, 16 females)
6 , amphetamine, dextroamphetamine, stimulant, lisdexamfetamine, and methylphenidate.
7 ntained when subgroups (ie, methylphenidate, lisdexamfetamine, and other amphetamines) were separatel
8 reen-detected populations; guided self-help, lisdexamfetamine, and topiramate were effective for redu
9                                              Lisdexamfetamine demonstrated superiority over placebo o
10                                     Evaluate lisdexamfetamine dimesylate (LDX) augmentation of antide
11                   The efficacy and safety of lisdexamfetamine dimesylate (LDX) vs placebo in binge ea
12              This multicenter study examined lisdexamfetamine dimesylate (LDX), a d-amphetamine prodr
13                                              Lisdexamfetamine dimesylate at dosages of 30, 50, or 70
14                                    To assess lisdexamfetamine dimesylate maintenance of efficacy in a
15 pen-label phase (dose optimization, 4 weeks [lisdexamfetamine dimesylate, 50 or 70 mg]; dose maintena
16  12) were randomized to placebo or continued lisdexamfetamine during a 26-week, double-blind, randomi
17                                              Lisdexamfetamine for binge eating disorder (4 RCTs; n =
18 eption of fluoxetine for bulimia nervosa and lisdexamfetamine for binge-eating disorder.
19                     Further investigation of lisdexamfetamine in BED is ongoing.
20                                              Lisdexamfetamine (LDX) has been suggested to be a safe a
21 eness of cognitive-behavioral therapy (CBT), lisdexamfetamine (LDX), and combined CBT+LDX, for BED co
22                                              Lisdexamfetamine (mean difference [MD], -6.50 [CI, -8.82
23 sdexamfetamine responders (placebo, n = 138; lisdexamfetamine, n = 137), the observed proportions of
24 nts and the central nervous system stimulant lisdexamfetamine reduce binge frequency in binge-eating
25 ased sympathetic nervous system arousal, and lisdexamfetamine reduced weight and appetite.
26 e, 50 or 70 mg]; dose maintenance, 8 weeks), lisdexamfetamine responders (</=1 binge eating day per w
27                            Of 275 randomized lisdexamfetamine responders (placebo, n = 138; lisdexamf
28                Cognitive behavioral therapy, lisdexamfetamine, SGAs, and topiramate reduced binge eat
29  months was lower in participants continuing lisdexamfetamine than in those randomized to placebo.
30 system arousal occurred more frequently with lisdexamfetamine than placebo (relative risk range, 1.63
31        The hazard for relapse was lower with lisdexamfetamine than placebo.
32 [small effect size; 95% CI, -0.51 to -0.06]; lisdexamfetamine vs placebo, Hedges g = 0.57 [medium eff
33 ased on a Cox proportional hazards model for lisdexamfetamine vs placebo, was 0.09 (95% CI, 0.04-0.23
34                       Compared with placebo, lisdexamfetamine was associated with higher rates of dry